Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation

Shuhei Kurosawa, Yoshimitsu Shimomura, Takayoshi Tachibana, Ken Ishiyama, Shuichi Ota, Takeshi Kobayashi, Naoyuki Uchida, Kentaro Fukushima, Takashi Ashida, Ken ichi Matsuoka, Junya Kanda, Tatsuo Ichinohe, Yoshiko Atsuta, Makoto Murata, Jun Aoki

Research output: Contribution to journalArticlepeer-review

1 Citation (Scopus)

Abstract

To date, there are no data focusing on outcomes of allogeneic hematopoietic stem cell transplantation (allo-HSCT) in patients with myelodysplastic/myeloproliferative neoplasms, unclassifiable (MDS/MPN-U). This study aimed to evaluate outcomes and prognostic factors in patients with MDS/MPN-U after allo-HSCT using Japanese nationwide registry data. The primary endpoint was 3-year overall survival (OS); secondary endpoints included the cumulative incidence of relapse and nonrelapse mortality (NRM). We evaluated the prognostic factors for 3-year OS by univariate analysis using the log-rank test. In our cohort of 86 patients with MDS/MPN-U, we found a 3-year OS of 48.5%, cumulative incidence of relapse of 23.7%, and NRM of 26.3%. The 3-year OS was significantly worse in patients age ≥50 years compared with those age <50 years (38.1% versus 65.0%; P = .049) and in patients with disease progression compared with those without disease progression (28.4% versus 57.2%; P = .042). Our results suggest that allo-HSCT may offer a curative option for patients with MDS/MPN-U, and that age and disease status could be important indicators in helping clinicians determine treatment options for these patients.

Original languageEnglish
Pages (from-to)1607-1611
Number of pages5
JournalBiology of Blood and Marrow Transplantation
Volume26
Issue number9
DOIs
Publication statusPublished - Sep 2020

Keywords

  • Allogeneic hematopoietic stem cell transplantation
  • Myelodysplastic/myeloproliferative neoplasms, unclassifiable

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Fingerprint

Dive into the research topics of 'Outcome of Allogeneic Hematopoietic Stem Cell Transplantation in Patients with Myelodysplastic/Myeloproliferative Neoplasms-Unclassifiable: A Retrospective Nationwide Study of the Japan Society for Hematopoietic Cell Transplantation'. Together they form a unique fingerprint.

Cite this